Ramos et al reported a score for evaluating a patient with acute myeloid leukemia (AML) who is treated with azacitidine. This is a hypomethylating agent that is usually given to patients who are unfit for more intensive chemotherapy. The authors are from multiple institutions in Europe.

To read more or access our algorithms and calculators, please log in or register.